UROKINASE

Urokinase was initially approved by the United States Food and Drug Administration (FDA) on June 5, 1996.

Urokinase is utilized to treat conditions marked by blood clot formation, such as deep vein thrombosis and pulmonary embolism, by dissolving clots and restoring blood flow. It may also be employed in acute ischemic stroke, peripheral arterial thrombosis, central venous catheter clotting, and select cases of heart attack to break down clots and improve blood circulation. However, its use necessitates careful medical evaluation and supervision, as individual factors and potential risks must be considered.

Urokinase is typically administered intravenously (IV) through a vein, allowing direct delivery into the bloodstream. This route ensures rapid distribution throughout the body, enabling its thrombolytic action to dissolve blood clots and restore blood flow in various medical conditions such as deep vein thrombosis, pulmonary embolism, and acute ischemic stroke.

Urokinase can cause common side effects like nausea, vomiting, diarrhea, rash, headache, hair loss, and increased susceptibility to infections. More serious side effects may include severe allergic reactions, liver problems, pancreatitis, severe bone marrow suppression, and an increased risk of developing malignancies. Promptly report any side effects to your healthcare provider for proper management and monitoring during the course of treatment.

Urokinase use can lead to significant bleeding, which may be life-threatening. This medication may trigger allergic reactions, presenting as rash, swelling, or breathing difficulties. It’s use may increase the risk of localized or systemic infections, particularly in cases involving catheter-related interventions. Patients with low platelet counts (thrombocytopenia) are at increased risk of bleeding. Its use may increase the risk of intracranial bleeding, particularly in patients with pre-existing conditions such as aneurysms or vascular malformations.

Immediate medical attention is necessary if allergic reactions symptoms occur. Patients with brain tumors or intracranial neoplasms should be closely observed when using this medication due to the risk of bleeding in the brain.Urokinase necessitates vigilant medical oversight and assessment to minimize adverse effects, ensure appropriate use, and manage potential complications.Patients with recent surgery or history of stroke require careful monitoring due to the potential for increased bleeding risk. Patients with kidney (renal) impairment require special consideration, as it is excreted through the kidneys and dose adjustments may be necessary.

When using Urokinase, it's important to take several precautions to ensure safe and effective treatment. Consider the potential risks and benefits, especially if you have a history of bleeding disorders, allergies, liver or kidney impairment, lung conditions, or recent surgery. Pregnant or breastfeeding individuals should consult their healthcare provider. Monitor for signs of bleeding, allergic reactions, or changes in blood pressure. Inform your healthcare provider about all medications and supplements you're taking. Be cautious if this affects your ability to drive or operate machinery. Patients with stroke history, recent trauma, hypertension, or clotting disorders need close monitoring. Promptly report any adverse effects, and maintain regular communication with your healthcare provider for tailored guidance throughout Uokinase therapy.

Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs, 12th edition, 2011, 852. KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting Coagulation, bleeding and thrombosis, 7th edition, 2013, 627. Syner-Medica Ltd, Electronic medicines compendium (EMC), [Revised on 27th Jul 2023] [ Accessed on 7th August 2023], https://www.medicines.org.uk/emc/product/264/smpc#gref